Viatris Inc.
VTRSHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Viatris Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America,. The company carries a $20.14B market cap, placing it firmly in the large-cap category. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Market Cap
$20.14B
Beta
0.90
P/E (TTM)
—
P/E (Fwd)
6.49
EPS (TTM)
$-0.30
EPS (Fwd)
$2.66
ROE
-2.0%
ROA
2.3%
Cash
$2.40B
Total Debt
$14.61B
Free CF
$2.24B
52W Change
94.7%
Annual Financials
Cash vs Debt
Viatris Inc. carries $14.61B in total debt against $2.40B in cash reserves — debt is roughly 6.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $2.24B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -2.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.3% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $17.89B (2021) to $14.30B (2025), a 20% decline worth watching.
Viatris Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VTRS.